Research & Education

ELCC 2014: Late and Chronic Toxicities of New Targeted Therapies


Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.

ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy


Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.

ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening

In search of non-invasive biomarkers

A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.

ELCC 2014: Cabazitaxel Fails to Meet the Primary Endpoint in a Randomised Phase II Study in SCLC Patients

Cabazitaxel failed to meet a primary endpoint of showing superior progression-free survival (PFS) and additionally showed less favourable median overall survival (OS) compared to topotecan in an international, randomised open-label phase II trial performed in patients with small-cell lung cancer (SCLC), who had progressed during or after first-line platinum-based chemotherapy

ELCC 2014: Mutational Spectrum of Patients Enrolled Into GALAXY-1 Study

A team of UK and USA researchers, led by Prof. Dean Fennell of the Thoracic Medical Oncology Department, University Hospital of Leicester, UK, performed a prospective exploratory liquid biopsy analysis with the aim of identifying somatic mutations in plasma as predictors of clinical outcome with ganetespib in the GALAXY-1 trial.

ELCC 2014: Diagnosis and Targeting Lung Adenocarcinoma with RET Fusion

In a large number of samples of lung adenocarcinoma the incidence of RET fusion, as detected by routine diagnostics, was higher than expected, according to a report by Dr Oliver Gautschi of the Clinic for Oncology, Kantonsspital, Luzern, Switzerland.